Analysis of the electron-stream effect in patients treated with partial breast irradiation using the 1.5 T MR-linear accelerator.
Cosmesis
Electron stream effect
MR linear accelerator
MRL
PROMs
Partial breast irradiation
Toxicity
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
28
09
2020
revised:
21
12
2020
accepted:
28
12
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
The hybrid magnetic resonance linear accelerator (MRL) has the potential to test novel concepts in breast cancer patients such as daily MR-guided real-time plan adaptation. Before starting clinical trials, preparatory studies for example of the MR-dependent electron stream effect (ESE) are necessary. To prospectively investigate the ESE, data from 11 patients treated with partial breast irradiation (PBI) at the 1.5 T MRL were evaluated. A bolus was placed on the chin and Median doses measured and simulated on top/ underneath the bolus were 1.91 / 0.62 Gy and 2.82 / 0.63 Gy, respectively. Median differences between calculations and measurements were 0.8 Gy and 0.1 Gy. At the conventional linac, median measured doses on top/ underneath the bolus were 0.98 and 1.37 Gy. No acute toxicity exceeding grade 2 was recorded. Cosmesis was good or excellent and patient reported outcome measures were mostly scored as none or mild. The dose due to the ESE is low, correctly predicted by the TPS and effectively minimized by a bolus.
Identifiants
pubmed: 33553697
doi: 10.1016/j.ctro.2020.12.005
pii: S2405-6308(20)30110-5
pmc: PMC7856390
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103-108Informations de copyright
© 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Déclaration de conflit d'intérêts
The MR-Linac research program is funded by the German Research Council (to D.T. and D.Z., ZI 736/2-1). Radiation Oncology Tübingen receives financial and technical support from Elekta AB (Stockholm, Sweden) under a research agreement. C.D.C. is supported by the Medical Faculty Tübingen (TüFF).
Références
Lancet Oncol. 2017 Feb;18(2):259-268
pubmed: 28094198
Br J Surg. 1999 Jan;86(1):84-7
pubmed: 10027366
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):791-800
pubmed: 22099046
Radiother Oncol. 2010 Mar;94(3):264-73
pubmed: 20181402
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Phys Med Biol. 2019 Jun 05;64(11):115029
pubmed: 30808017
Lancet. 2014 Feb 15;383(9917):603-13
pubmed: 24224997
Clin Transl Radiat Oncol. 2019 Apr 01;18:68-73
pubmed: 31341979
Strahlenther Onkol. 2018 Jan;194(1):50-59
pubmed: 28916952
Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79
pubmed: 27866865
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):720-727
pubmed: 30197095
Clin Transl Radiat Oncol. 2020 Apr 29;23:35-42
pubmed: 32395640
Clin Transl Radiat Oncol. 2019 Apr 08;18:66-67
pubmed: 31341978
Clin Transl Radiat Oncol. 2019 Apr 12;18:80-86
pubmed: 31341981
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):785-792
pubmed: 27788951
Ann Oncol. 2019 Oct 1;30(10):1674
pubmed: 31236598
Med Phys. 2019 Mar;46(3):1467-1477
pubmed: 30666678
Phys Med Biol. 2018 May 01;63(9):095001
pubmed: 29595150
Radiother Oncol. 2019 May;134:50-54
pubmed: 31005224
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):10-8
pubmed: 20421148
Radiother Oncol. 2020 Mar;144:46-52
pubmed: 31710943
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1179-85
pubmed: 23182700
Radiother Oncol. 2020 Apr;145:30-35
pubmed: 31874347
Clin Transl Radiat Oncol. 2020 May 15;23:72-79
pubmed: 32490218
Lancet. 2017 Sep 9;390(10099):1048-1060
pubmed: 28779963
J Appl Clin Med Phys. 2017 Nov;18(6):62-70
pubmed: 28901729
Clin Transl Radiat Oncol. 2019 Apr 02;18:54-59
pubmed: 31341976
Front Oncol. 2020 Jul 28;10:1107
pubmed: 32850318
Radiother Oncol. 2009 Apr;91(1):16-22
pubmed: 19178972